HERA

Disease site: Breast Cancer

Treatment Modality: Chemotherapy

Status: In active follow-up

This is an international study run under the auspices of the Breast International Group.

There are five collaborative groups within the UK which participate in the study:

• National Cancer Research Institute Breast Clinical Studies Group (NCRI BCSG)
• Anglo Celtic Cooperative Oncology Group (ACCOG)
• Yorkshire Breast Cancer Research Group (YBCRG)
• European Organisation for Research and Treatment of Cancer (EORTC)
• International Collaborative Cancer Group (ICCG)

More information about the trial can be found on the HERA website.

UK Chief Investigator: Professor I. E. Smith, Royal Marsden Hospital, Sutton.

Source of funding: Roche.

ISRCTN: 82811952.

The ICR-CTSU are also coordinating the UK’s contribution to TransHERA. This translational research program aims to collect breast cancer tissue from patients entered into the HERA trial. The tissue will be used for future research into the response to Herceptin therapy.

TransHERA Chief Investigators:

• Professor M. Dowsett, Royal Marsden Hospital, London
• Professor B. Leyland-Jones, Gerald Bronfman Centre for Clinical Research in Oncology, McGill University, Montreal, Canada